1. Home
  2. Directory
  3. Arizona
  4. Scottsdale
  5. Radiology
  6. NPI Profile
  7. Prescriptions 1124093539

GREGORY A MAGGASS MD
Prescription History 1124093539
Radiology - Radiation Oncology in Scottsdale, AZ

NPI Status: Active since February 20, 2006

Contact Information

9055 E DEL CAMINO DR
STE 200
SCOTTSDALE, AZ
ZIP 85258
Phone: (480) 922-4600
Fax: (480) 922-5231

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GREGORY A MAGGASS MD, an active Radiation Oncology specialist practicing in Scottsdale, AZ. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 323 documented patient claims. Among these therapy options, the most frequently utilized medication is Pilocarpine Hcl, which accounts for 127 claims alone.

Medication Index

A
O
P
T
No matching medications currently found on file.

Alfuzosin Hcl Er

Generic Formulation: Alfuzosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 71
30-Day Fills 138.8
Days Supply 4,140
AZ State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills119.4
Peer Average Days Supply3,575
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 47.9% more claims than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,857.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.17

State Avg Cost Per Claim

$28.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Alfuzosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 45
30-Day Fills 45.0
Days Supply 413
AZ State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.0
Peer Average Days Supply297
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 95.7% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $909.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.21

State Avg Cost Per Claim

$28.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Pilocarpine Hcl

Generic Formulation: Pilocarpine HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 127
30-Day Fills 127.0
Days Supply 683
AZ State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills44.1
Peer Average Days Supply1,283
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 429.2% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,202.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.47

State Avg Cost Per Claim

$90.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.

Therapeutic Applications

This medication is used to treat symptoms of dry mouth due to a certain immune disease (Sjogren's syndrome) or from saliva gland damage due to radiation treatments of the head/neck for cancer. Pilocarpine belongs to a class of drugs known as cholinergic agonists. It works by stimulating certain nerves to increase the amount of saliva you produce, making it easier and more comfortable to speak and swallow.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 80
30-Day Fills 159.0
Days Supply 4,770
AZ State Average Benchmarks
Peer Average Claims75.0
Peer Average 30-Day Fills185.3
Peer Average Days Supply5,519
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,186.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.83

State Avg Cost Per Claim

$20.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GREGORY A MAGGASS MD provides transparency into local medical care patterns within Scottsdale, AZ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.